BioSpace News Archive

Revive Therapeutics Ltd., a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to provide a corporate update on its plans for the Company’s coronavirus disease and infectious diseases programs.

Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”)

Athersys, Inc. announced that its partner in Japan, HEALIOS K.K., exercised in full its warrant to purchase shares of Athersys common stock.

Altimmune, Inc., a clinical-stage biopharmaceutical company, announced that it is launching a collaboration with the University of Alabama at Birmingham on the development of its single-dose, intranasal COVID-19 vaccine, named AdCOVID.

Tim Armstrong, Chair of the Board of Directors of the Radiation Safety Institute of Canada, is pleased to announce two leadership changes at the Institute.

Soligenix, Inc. announced its recent accomplishments and financial results for the year ended December 31, 2019.

LifeMax Laboratories, Inc. announced the formation of AmMax Bio, Inc. and an exclusive worldwide license from Amgen for the right to develop, manufacture and commercialize AMG 820, a monoclonal antibody against the colony-stimulating factor 1 receptor that has completed Phase I/II clinical studies in solid tumors.

Correvio Pharma Corp. reported financial results for the full year ended December 31, 2019 and commented on recent accomplishments and plans.

Compass Therapeutics announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company’s lead investigational therapy, CTX-471, which is currently being evaluated in a Phase 1 clinical trial.

Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with etoposide and a choice of carboplatin or cisplatin chemotherapy